Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.

Liu J, Nie XY, Zhang Y, Lu Y, Shi LW, Wang WM.

Chin Med J (Engl). 2015 Aug 20;128(16):2183-8. doi: 10.4103/0366-6999.162515.

2.

Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.

Kreutz RP, Breall JA, Kreutz Y, Owens J, Lu D, Bolad I, von der Lohe E, Sinha A, Flockhart DA.

Thromb Res. 2012 Aug;130(2):198-202. doi: 10.1016/j.thromres.2012.02.049. Epub 2012 Mar 28.

3.

Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.

Park KJ, Chung HS, Kim SR, Kim HJ, Han JY, Lee SY.

Korean J Lab Med. 2011 Apr;31(2):91-4. doi: 10.3343/kjlm.2011.31.2.91.

4.

The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.

Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US.

Am Heart J. 2011 Mar;161(3):598-604. doi: 10.1016/j.ahj.2010.12.011.

Supplemental Content

Loading ...
Write to the Help Desk